Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.7152W HIGH $3.40
Volume
98.68 K
Value Traded
164.08 K
Short % Float
1.98%
-3.81%Week
-4.72%1 Month
-46.84%3 Month
-27.34%6 Month
-97.89%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
26.92 M
EPS (TTM)
-0.27
P/E Ratio
-
Ent. Value
26.89 M
Total Shares
26.65 M
Float Shares
25.51 M
Insiders
18.11%
Institutions
3.50%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ABVC Catalyst Timeline
Dated clinical, regulatory and corporate events for ABVC BioPharma, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for ABVC BioPharma, Inc.
158Total events
0Upcoming
40Tier-1 (high impact)
2006 to 2026Coverage
Event history 50
●Quarterly UpdateCorporate
Filed Annual Report on Form 10-K for fiscal year ended December 31, 2025
●Quarterly UpdateCorporate
Reported Q2 2025 financial results with diluted loss per share of $(0.13)
▲Partnership / LicenseCorporate
Received $350,000 in licensing revenue from AiBtl BioPharma, OncoX BioPharma, and ForSeeCon Eye Corporation in July 2025
●AcquisitionCorporate
Completed acquisition of farmland in Taiwan valued at ~$3.3 million for R&D and GMP expansion
▲Quarterly UpdateCorporate
Announced 2024 financial results with revenue up 234%, expenses down 21%, EPS improvement of 77%
▲Quarterly UpdateCorporate
Nasdaq granted additional 180-day grace period to regain bid price compliance
▲Trial InitiationABV-1601Trial
Phase I study for ABV-1601 to initiate by end of 2024
MDD in cancer patientssource ↗
▲Trial CompletionABV-1504Trial
Phase II trial completed for ABV-1504 in MDD
Major Depressive Disorder (MDD)source ↗
▲Patent GrantedABV-1504IP / Competition
US patent granted for Polygala extract for MDD
major depressive disordersource ↗
▲Patent GrantedABV-1505IP / Competition
US patent granted for Polygala extract for ADHD
attention deficit hyperactivity disordersource ↗
▲Trial CompletionABV-1504Trial
Phase II trial for MDD completed successfully
major depressive disordersource ↗
▲Trial InitiationABV-1505Trial
Phase IIb trial for ADHD initiated at UCSF and five other sites in Taiwan
attention deficit hyperactivity disordersource ↗
▲Other Regulator MilestoneVitargusEx-US Regulatory
TGA approval to initiate next trial phase for Vitargus in Australia
retinal detachmentsource ↗
▲Manufacturing MilestoneVitargusCMC / Inspection
Approval to set up pilot GMP facility for Vitargus in Taiwan
retinal detachmentsource ↗
◆Interim AnalysisABV-1505Trial
Interim report for ADHD Phase IIb expected by end of Q3 2024
attention deficit hyperactivity disordersource ↗
▲Milestone PaymentCorporate
Milestone payment received from ForSeecon Eye Corporation for Vitargus licensing
▲Milestone PaymentVitargusCorporate
Initial $116,000 milestone payment received for Vitargus licensing
retinal detachmentsource ↗
▲Partnership / LicenseCorporate
Exclusive license agreement with OncoX for BLEX 404
Myelodysplastic Syndromesource ↗
▲Partnership / LicenseCorporate
ABVC and OncoX enter definitive agreement for BLEX 404 combination therapy
Triple Negative Breast Cancersource ↗
▲Partnership / LicenseCorporate
ABVC and OncoX enter definitive agreement for combination therapy collaboration
Pancreatic Cancersource ↗
▲Partnership / LicenseCorporate
Global licensing agreement with OncoX for BLEX 404
Non-Small Cell Lung Cancer (NSCLC)source ↗
◆Trial CompletionABV-1701Trial
Vitargus Phase II study expected completion
retinal detachment and vitreous hemorrhagesource ↗
▲Partnership / LicenseVitargusCorporate
Global licensing agreement with ForSeeCon Eye Corporation for Vitargus
ophthalmologysource ↗
◆AcquisitionCorporate
Acquisition of land in Taoyuan City, Taiwan for $2.96 million via equity transfer
▲IND ClearanceABV-1519IND
Taiwan FDA approval for IND ABV-1519
Advanced Inoperable or Metastatic EGFR Wild-type Non-Small Cell Lung Cancersource ↗
▲Milestone PaymentCorporate
Collected $696,007 in milestone payments from licensing partners in 2024
●Manufacturing MilestoneVitargusCMC / Inspection
Completion of pilot GMP facility construction for Vitargus in Hsinchu Biomedical Science Park
retinal detachmentsource ↗
▲Trial InitiationABV-1601Trial
Phase I study for MDD in cancer patients to initiate by end of 2024
major depressive disorder in cancer patientssource ↗
▲Enrollment CompleteABV-1701Trial
Phase II trials of Vitargus expected to complete by end of 2023
Retina reattachmentsource ↗
●End Of Phase 2 MeetingABV-1504FDA Meeting
End-of-Phase II meeting preparation with FDA for ABV-1504
Major Depressive Disordersource ↗
◆Interim AnalysisABV-1505Trial
Interim report for ADHD Phase IIb trials expected
Attention-Deficit/Hyperactivity Disordersource ↗
▲Partnership / LicenseCorporate
Global licensing agreement with AIBL for CNS drugs
CNS (MDD and ADHD)source ↗
▲Partnership / LicenseCorporate
Multi-year global licensing agreement with AIBL for CNS drugs (MDD and ADHD)
major depressive disorder, attention deficit hyperactivity disordersource ↗
Past FDA Catalysts and PDUFA Decisions
How ABVC actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2023-12-31 | ABV-1505 | Phase 2b interim results | Phase 2b |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D28 / 100
Pipeline Score
$4M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.2x
rNPV / MCap
Top 75%
Micro Cap(rank 494 of 658)
Percentile Rank
ABVC BioPharma, Inc. faces pipeline headwinds (28/100), with $808M risk-adjusted pipeline value, led by PDC-1421 in Attention-Deficit Hyperactivity Disorder (ADHD) (Phase 2), across $58B in total addressable markets, but cash runway is a concern.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PDC-1421 Small moleculeNCT01774045 | Major Depressive Disorder | Phase 2 | COMPLETED | 114 | Jul 1, 2013 |
Clinical Trial Results
Readouts, endpoints and source filings for every ABVC program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ABVC
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in ABVC for Q2 2026. | ||||
ABVC Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ABVC ranks across every disease it competes in
Competitive Position is a premium feature
See how ABVC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialABVC News
ABVCABVC BioPharma Reports 2025 Form 10-K Total Assets Increase 179% to $21.06 Million as Company Strengthens Asset-Backed Licensing Model Silicon Valley, CA (
ABVC BioPharma reported a significant increase in total assets, rising 179% to $21.06 million for the fiscal year ended December 31, 2025, according to their Form 10-K filing. The company emphasizes its strategic acquisition of land assets in Asia as a cornerstone of its asset-backed licensing model. This approach is designed to separate development risks from long-term value, enhancing the financial efficiency of the company. ABVC BioPharma aims to evolve towards a hybrid asset model that combines real assets with its existing intellectual property-driven framework.
Read more →ABVC▲ +5.7%on this news
ABVC BioPharma Reports 230% YoY Licensing Revenue Growth and 181% Asset Expansion in Q3 2025 Silicon Valley, CA (
ABVC BioPharma reported impressive financial results for Q3 2025, highlighting a 230% increase in year-over-year licensing revenue and a 181% expansion in assets. The company's focus on an asset-light business model has allowed it to pursue growth through partnerships and collaborations, particularly in the central nervous system, ophthalmology, and oncology sectors. CEO Dr. Uttam Patil expressed confidence in the company’s strategic priorities aimed at long-term shareholder value. ABVC's active pipeline includes six drugs and one medical device currently under development.
Read more →ABVCABVC BioPharma, Inc. Reports 103% Year-Over-Year Asset Growth and Secures $350K in Post-Quarter Licensing Revenue in Q2 2025 Silicon Valley, CA (
ABVC BioPharma, Inc. has reported a significant 103% increase in year-over-year assets and secured $350,000 in licensing revenue in July 2025. The company's second-quarter results show a reduced diluted loss per share, reflecting its focus on operational efficiency. ABVC's recent acquisition of farmland in Taiwan aims to support its research and manufacturing capabilities in Asia. The CEO highlighted these initiatives as part of the company's strategy for sustainable long-term growth and enhancing shareholder value.
Read more →ABVC▼ -13.1%on this news· ran to -28% by day 1
ABVC BioPharma Regains Nasdaq Minimum Bid Price Compliance Silicon Valley, CA
ABVC BioPharma has successfully regained compliance with Nasdaq's minimum bid price, confirming a closing bid price above $1.00 for 10 consecutive trading days. This achievement highlights the company's turnaround strategy and commitment to enhancing shareholder value. Additionally, ABVC is entering discussions with major pharmaceutical and AI firms for the co-development of its Phase III-ready candidates for Major Depressive Disorder and ADHD. The company is focusing on building a platform for future commercialization while maintaining high listing standards.
Read more →ABVCABVC BioPharma Announces First Quarter 2025 Financial Results and Strategic Planning for AI-Driven Agricultural Project in Taiwan Silicon Valley, CA
ABVC BioPharma announced its financial results for Q1 2025 and outlined plans for a potential AI-enabled agricultural project in Taiwan. The company recognized a land asset valued at $7.67 million for this development, which aims to enhance agricultural practices through precision technology. Despite optimistic projections, the company acknowledges that the project's realization is uncertain. Additionally, financial data reflects a significant operating loss compared to the previous year, highlighting ongoing challenges as the company seeks to enhance its drug pipeline and infrastructure.
Read more →ABVC▲ +8.3%on this news
ABVC BioPharma Announces 2024 Financial Results Revenue Surges 234%, Expenses Down 21%, EPS Improves 77%, with Over $18.3 Million 1 Licensing Incomes Available Silicon Valley , CA (
ABVC BioPharma announced its financial results for the fiscal year ended December 31, 2024, highlighting a significant revenue growth of 234% to $509,589, primarily driven by licensing payments. Expenses also decreased by 21% to $5.21 million, showcasing improved cost management. Moreover, the company's earnings per share improved by 77%, with a narrower net loss of $4.90 million. ABVC has the potential to receive up to $18.3 million in additional milestone payments under its current licensing agreements, enhancing its growth prospects.
Read more →ABVCABVC BioPharma, Inc. Granted Additional 180-Day Grace Period to Regain Compliance with Nasdaq Bid Price Requirement Fremont, CA (
ABVC BioPharma, Inc. has been granted an additional 180-day grace period by Nasdaq to meet its minimum bid price requirement, extending the deadline to July 7, 2025. The company is committed to regaining compliance by monitoring its stock price and taking necessary steps during this period. ABVC has shown compliance with all other Nasdaq listing requirements and is optimistic about its future growth and development plans.
Read more →ABVCABVC BioPharma Inc. Reports Q3 2024 Financial Results and Operational Milestones ABVC BioPharma Achieved its First Operational Profit, with a 102% Improvement over the Third Quarter of Last Year. Incremental Payments Rec
ABVC BioPharma, Inc. reported its Q3 2024 financial results, achieving its first operational profit and a 102% improvement compared to the prior year. The company is advancing in clinical trials for its major depressive disorder and ADHD programs, with important regulatory moves for its vitreous substitute, Vitargus. Recent licensing agreements have positioned ABVC to potentially generate significant revenue streams. Despite a negative EPS due to interest expenses, management expressed confidence in their growth trajectory and future value creation.
Read more →ABVC▲ +6.2%on this news
Corporate Overview NASDAQ: ABVC 2024 2 Forward Looking Statements This presentation contains summary information about ABVC BioPharma, Inc . ("ABVC") as of the date hereof . The information in this presentation is of gen
ABVC BioPharma has released an overview detailing its corporate strategy and financial performance for Q2 2024. The company reported a notable increase in revenue from $6,109 in Q2 2023 to $117,142 in the same quarter of 2024. Additionally, ABVC's earnings per share improved significantly. Its pipeline includes promising candidates for Major Depressive Disorder and ADHD, with recent advancements in patent approvals and licensing agreements suggesting positive future prospects.
Read more →ABVC▼ -5.2%on this newsshared move
ABVC BioPharma Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements Executed Global Licensing Agreements that could provide up to $292 million in income Received Cash Milestone Incomes of $116,000 Ach
ABVC BioPharma Inc. reported strong financial results for Q2 2024, including significant licensing agreements that could provide up to $292 million in income. The company achieved an 86.8% year-over-year improvement in earnings per share and recorded substantial revenue growth. While the financial outlook appears promising, the potential income from licensing agreements remains contingent on product success. Recent patent approvals and advancements in clinical trials further bolster ABVC's strategic position in the biopharmaceutical market.
Read more →ABVC▼ -9.1%on this news
Immunity Boosting Combination Therapy for Myelodysplastic Syndrome Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Eligible to Receive Aggregate Income of $13.75M and Royalties of up to $12.50M Fremont,
ABVC BioPharma has formed a significant collaboration with OncoX BioPharma to develop a combination therapy for Myelodysplastic Syndrome (MDS), announcing the potential for an aggregate income of $13.75M and royalties up to $12.50M. The partnership marks a hopeful advance in MDS treatment, aiming to improve patient outcomes through innovative therapeutic approaches. However, there are uncertainties regarding both the financial outcomes and the success of the therapy, as regulatory approvals and market dynamics remain unpredictable.
Read more →ABVCPromising Combination Therapy for Tripple Negative Breast Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, Potential Income of $13.75M and Royalties of up to $12.50M Fremont, CA (
ABVC BioPharma has announced a partnership with OncoX BioPharma to develop a combination therapy for Triple Negative Breast Cancer (TNBC). The collaboration includes a significant financial agreement potentially worth up to $13.75 million, along with royalties on future sales. This effort aims to improve treatment options for TNBC, a challenging subtype of breast cancer that currently lacks effective therapies. Both companies will contribute their expertise in drug development towards clinical trials and regulatory proceedings. However, the outcome and timeline for the therapy remain uncertain.
Read more →ABVCCombination Therapy Holds Promise for Pancreatic Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M Fremont, CA (
ABVC BioPharma, in collaboration with OncoX BioPharma, announced a partnership to develop a combination therapy for pancreatic cancer. This collaboration includes a license fee of $12.5 million and milestone payments as part of their agreement, signaling a strong financial expectation from the partnership. The therapy aims to improve patient outcomes by leveraging the strengths of both companies in oncology treatment. However, uncertainties remain about the successful development and commercialization of the product, alongside potential challenges in financing and regulatory approvals.
Read more →ABVCABVC Biopharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M Fremont, CA (
ABVC Biopharma has entered a global licensing agreement with OncoX to develop and distribute a botanical drug extract for treating Non-Small Cell Lung Cancer (NSCLC). The agreement anticipates an aggregate income of $13.75 million and royalties of up to $12.50 million, contingent on future sales. This collaboration is aimed at enhancing treatment options and expediting patient access to innovative therapies. Both companies will combine their strengths to advance the clinical program for the promising therapy BLEX 404.
Read more →ABVC▲ +21.9%on this news
ABVC Biopharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M Fremont, CA (
ABVC Biopharma has entered a global licensing agreement with ForSeeCon Eye Corporation for its ophthalmology product, Vitargus. The deal includes an initial licensing payment of $30 million and royalties of up to $60 million based on future sales. ABVC's CEO highlights the potential to improve patient quality of life during vitrectomy procedures through this collaboration. This agreement positions ABVC to expand its reach in the ophthalmic market, which is projected to grow significantly over the next several years.
Read more →ABVCABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update Fremont, CA (
ABVC BioPharma has released its annual financial results for 2023, highlighting a commitment to improve health outcomes through botanically derived solutions. Significant developments include a global licensing agreement for CNS drugs, which positions the company toward profitability with potential royalties. Additionally, the company has regained Nasdaq compliance and expanded its patent portfolio for various health indications. However, concerns remain regarding its reliance on external financing and the impact of convertible notes on shareholder value.
Read more →ABVC▼ -7.1%on this news
ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share Fremont, CA
ABVC BioPharma has signed an agreement to acquire real estate in Taoyuan City, Taiwan, valued at approximately $2.96 million. The acquisition, executed through an equity transfer at a price of $3.50 per share, is intended to support the development of plant factories to grow raw materials for ABVC's botanical drug pipeline. This investment is viewed as an opportunity to enhance shareholder equity and foster collaborations in the Asian healthcare market. The transaction involves a related party, which may introduce governance considerations but reflects strategic positioning in a growing sector.
Read more →ABVC▲ +11.6%on this news· ran to +51% by day 3
ABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results FREMONT, CA
ABVC BioPharma reported its third-quarter financial and operational results, showcasing progress in clinical trials and strategic partnerships. The company announced successful Phase II trial results for its drug ABV-1504 aimed at treating Major Depressive Disorder, with plans for a Phase III meeting with the FDA. It has also formed a licensing agreement with Xinnovation for its ADHD and MDD drugs, which could yield up to $20 million. The establishment of a partnership with Zhonghui for a health initiative in China was also highlighted.
Read more →ABVC▼ -7.2%on this news
ABVC Executes Cooperation Agreement for Strategic Investments Fremont, CA
ABVC BioPharma, Inc. has announced a Cooperation Agreement with Zhonghui United Technology to exchange a 20% ownership stake in a real estate property. Valued at approximately $7.4 million, this agreement will support the establishment of a healthcare center focusing on senior living and various medical care areas. The collaboration aims to contribute to rural revitalization and foster innovation in ABVC's target fields, including Oncology and Ophthalmology. This partnership signifies ABVC's commitment to company growth and global expansion in the biopharmaceutical sector.
Read more →ABVC▼ -8.8%on this news· ran to -20% by day 3
ABVC BioPharma Regains Compliance with Nasdaq's Minimum Bid Price Requirement Fremont, CA (
ABVC BioPharma has announced that it has regained compliance with Nasdaq's minimum bid price requirement, as it managed to maintain a closing bid price of $1.00 per share from July 25 to August 7, 2023. This compliance followed a notification in August 2022, when the company was warned of its non-compliance. ABVC is a clinical-stage biopharmaceutical company with an active pipeline that includes six drug candidates and one medical device. The company aims to conduct further clinical trials leveraging technology from esteemed research institutions to optimize product development.
Read more →About ABVC BioPharma, Inc.
Headquarters44370 OLD WARM SPRINGS BLVD., FREMONT, CA, 94538
Founded1990
BIOPHARMAWATCH ELITE PLUS
Trade the next ABVC catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime